CAPP2 long term follow up: aspirin protects against hereditary cancer


Session type:

John Burn1, John Mathers1, Anne-Marie Gerdes1, Marie-Luise Bisgaard2, D. Gareth Evans3, Diana Eccles4, Annika Lindblom5, Finlay Macrae6, Eamonn Maher7, Jukka-Pekka Mecklin8, Gabriela Moeslein9, Sylviane Olschwang10, Raj Ramesar11, Hans Vasen12, Juul Wijnen13, Gail Barker1, Faye Elliott14, Henry Lynch15, D. Timothy Bishop14

1Newcastle University, UK, 2University of Copenhagen, Denmark, 3St Marys Hospital, Manchester, UK, 4University of Southampton, UK, 5Karolinska Hospital, Stockholm, Sweden, 6The Royal Melbourne Hospital, Melbourne, Australia, 7Birmingham Women's Hospital, UK, 8Jyvskyl Central Hospital, Finland, 9St. Josefs-Hospital Bochum-Linden, Germany, 10Institut Paoli Calmettes, Marseille, France, 11University of Cape Town, South Africa, 12Foundation for Detection of Hereditary Tumours, Leiden, Netherlands, 13Leiden University Medical Center, Netherlands, 14University of Leeds, UK, 15Creighton University School of Medicine, Omaha, USA



The CAPP2 Study evaluated 600mg enteric coated aspirin and/or 30gms of Novelose (resistant starch) in a double blind factorial RCT in 1071 carriers of Lynch syndrome over a treatment period of 1 to 4 years, mean 29 months.


The trial, reported in December 2008 [1], showed that there was no difference between the treatment and placebo groups for new colorectal neoplasia.